VivoSeq
Hematology

Hemolytic Anemia

26

Pipeline Programs↗

17

Active Trials↗

16

Companies Involved↗

Hemolytic Anemia is an emerging landscape with 26 programs across 16 companies. The most active players are China Immunotech (Beijing) Biotechnology Co., Ltd., Grit Biotechnology, Johnson & Johnson. 1 therapy is approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

27/100

Mech. Concentration

36/100

Completion Rate

92/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

China Immunotech (Beijing) Biotechnology Co., Ltd.

1 program

Phase 1G

Grit Biotechnology

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 1A

Amphastar Pharmaceuticals, Inc.

1 program

Phase 1F

Fundamenta Therapeutics, Ltd.

1 program

Phase 1S

Shanghai YingLi Pharmaceutical Co. Ltd.

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

66%

Small molecule

19 of 29 classified programs — the dominant modality here.

34%ALL OTHERSCell therapy517%Monoclonal antibody414%Protein / enzyme13%

Small molecule leads; the ring shows all 29 classified programs, each share of the total. Modality classified for 100% of 35 pipeline programs.

Analysis

Trial Status

33

clinical trials

Completed11 · 33%
Not yet recruiting9 · 27%
Recruiting4 · 12%
Unknown status4 · 12%
Active, not recruiting3 · 9%
Enrolling by invitation1 · 3%
Other1 · 3%

Clinical Trials

Trial Activity

33 trials

CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT06212154·13 enrolled
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Recruiting·GGrit Biotechnology·Phase 1·NCT07205315·28 enrolled
Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study
Recruiting·—·Phase 2·NCT05089227·72 enrolled
Second-line Treatment of Primary Autoimmune Hemolytic Anemia
Recruiting·—·Phase 3·NCT05057468·30 enrolled
The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia
Active, not recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04398459·18 enrolled
HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Active, not recruiting·HHutchison Medipharma Limited·Phase 2/3·NCT05535933·110 enrolled
CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.
Active, not recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT06231368·6 enrolled
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Autoimmune Hemolytic Anemia
Not yet recruiting·ZZhejiang University·Phase 1·NCT06920446·18 enrolled
A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT07287930·13 enrolled
A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA)
Not yet recruiting·—·N/A·NCT06847607·20 enrolled
Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy
Not yet recruiting·JJuventas Cell Therapy Ltd.·Phase 1·NCT07091370·12 enrolled
A Single-arm Phase 2 Prospective Clinical Study of Enatumab in the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia
Not yet recruiting·—·Phase 2·NCT07190261·3 enrolled
A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT06770504·7 enrolled
A Single-arm Phase 2 Prospective Clinical Study of Linprixel in the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia
Not yet recruiting·PPeking Union Medical College Hospital·N/A·NCT07149818·22 enrolled
Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic Anemia
Not yet recruiting·CChina Immunotech (Beijing) Biotechnology Co., Ltd.·Phase 1·NCT07453836·13 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)